Skip to main content

Table 2 Predictors of reduced left ventricular ejection fraction during study follow-up

From: Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study

 

Univariate

Model 1

Model 2

Model 3

Female sex

0.31 (0.01-1.01)

0.23 (0.06-0.95)

0.35 (0.07-1.70)

–

Age

1.04 (1.00-1.08)

1.06 (1.01-1.11)

1.07 (1.01-1.13)

–

Basal LVEF

1.16 (1.08-1.25)

1.16 (1.08-1.25)

1.16 (1.07-1.25)

–

Basal hsCRP (Q4 vs Q1)

2.11 (0.68-6.51)

4.74 (1.03-21.8)

3.52 (0.73-17.1)

5.30 (0.04-659)

Basal PCSK9 (Q4 vs Q1)

0.85 (0.28-2.61)

1.88 (0.40-8.83)

2.63 (0.47-14.7)

17.1 (1.48-198)

Basal NT-proBNP (Q4 vs Q1)

1.26 (0.36-4.42)

0.84 (0.19-3.80)

0.83 (0.16-4.25)

0.63 (0.11-3.77)

Basal FABP3 (Q4 vs Q1)

1.45 (0.44-4.71)

2.33 (0.55-9.94)

1.82 (0.34-9.81)

2.67 (0.38-18.5)

  1. Data are OR (95% CI). For biomarkers, the lowest quartile of plasma concentration was used as reference group. LVEF Left ventricular ejection fraction, hsCRP High-sensitivity C-reactive protein, PCSK9 Proprotein convertase subtilisin kexin 9, NT-proBNP N-terminal prohormone of brain natriuretic peptide, FABP3 Heart-type fatty acid binding protein. Model 1 includes sex, age and baseline LVEF as independent variables. Model 2 includes all variables in Model 1 plus number of obstructed coronary vessels and percent maximal coronary obstruction. Model 3 includes all variables in model 2 plus change in the respective biomarker (final-basal plasma concentration)
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X